Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.62 |
| ▸ | CSF1R | P07333 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 5/20 | 0.59 |
| ▸ | BRAF | P15056 | 7/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | CLK1 | P49759 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 5/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249617 | 0.96 | KIT (0.61) | KITCSF1RABL1BRAFHTT | |
| SCHEMBL4254621 | 0.90 | KIT (0.77) | KITABL1BRAFEGFR | |
| SCHEMBL4260023 | 0.90 | HTT (0.66) | KITBRAFHTTCLK1MAPK1 | |
| SCHEMBL13660025 | 0.90 | KIT (0.67) | KITCSF1RABL1BRAFHTT | |
| SCHEMBL4255705 | 0.89 | KIT (0.62) | KITABL1BRAFHTTEGFR | |
| SCHEMBL4256157 | 0.89 | KIT (0.64) | KITCSF1RABL1BRAFHTT | |
| SCHEMBL18484171 | 0.87 | KIT (0.81) | KITCSF1RABL1BRAFHTT | |
| SCHEMBL4249619 | 0.87 | KIT (0.63) | KITCSF1RABL1BRAFHTT | |
| SCHEMBL4254623 | 0.86 | HTT (0.64) | KITHTTCLK1MAPK1ATM | |
| SCHEMBL17313595 | 0.86 | KIT (0.74) | KITCSF1RABL1BRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | claimed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | claimed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | claimed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | KIT 683/4885CSF1R 891/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.